Description
A PGF2α analog and prodrug form of (+)-fluprostenol; an FP receptor agonist (EC50 = 40.2 nM for induction of phosphoinositide turnover in HEK293 cells expressing the human ocular FP receptor); topical application induces miosis in conscious cats in a dose-dependent manner at 0.01, 0.03, and 0.1 μg; reduces intraocular pressure in a cynomolgus monkey model of ocular hypertension when administered topically at 0.1 and 0.3 μg twice per day
Formal name: 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-buten-1-yl]cyclopentyl]-5Z-heptenoic acid, 1-methylethyl ester
Synonyms: 16-m-trifluoromethylphenoxy tetranor PGF2α isopropyl ester|AL-6221|Flu-Ipr|Travoprost
Molecular weight: 500.6
CAS: 157283-68-6
Purity: ≥98%
Formulation: A solution in ethanol
Product Type|Biochemicals|Lipids|Prostaglandins||Product Type|Biochemicals|Receptor Pharmacology|Agonists||Research Area|Lipid Biochemistry|Cyclooxygenase Pathway||Research Area|Neuroscience|Ophthalmology